PMID- 34449869
OWN - NLM
STAT- MEDLINE
DCOM- 20211220
LR  - 20220223
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 150
IP  - 1
DP  - 2022 Jan 1
TI  - Circulating C-reactive protein increases lung cancer risk: Results from a 
      prospective cohort of UK Biobank.
PG  - 47-55
LID - 10.1002/ijc.33780 [doi]
AB  - Chronic inflammation has been associated with the development of lung cancer. In 
      this study, we examined the association between C-reactive protein (CRP) and lung 
      cancer in a prospective cohort study and used Mendelian randomization (MR) to 
      clarify the causality. We included 420 977 participants from the UK Biobank (UKB) 
      in the analyses; 1892 thereof were diagnosed with lung cancer during the 
      follow-up. Hazards ratios (HRs) of CRP concentrations were estimated by Cox 
      proportional hazard models and two approaches of MR analysis were performed. 
      Besides, we added CRP concentrations to epidemiological model of lung cancer to 
      evaluate its prediagnostic role through time-dependent receiver operating 
      characteristic curve analysis. Elevated CRP levels were associated with a 22% 
      increased lung cancer risk per 1 SD increase (HR = 1.22, 95% confidence interval 
      [CI] = 1.18-1.26). Positive associations were observed in small cell lung cancer 
      (HR = 1.21, 95% CI = 1.10-1.33), lung adenocarcinoma (HR = 1.17, 
      95% CI = 1.11-1.23) and lung squamous cell carcinoma (HR = 1.22, 
      95% CI = 1.14-1.31). No genetical association of circulating CRP levels and lung 
      cancer risk was observed in MR analysis. When added to a risk model of lung 
      cancer, CRP improved the performance of model as long as 8 years among current 
      smokers (basic model: C-statistic = 0.78 [95% CI = 0.75-0.80]; CRP model: 
      C-statistic = 0.79 [95% CI = 0.76-0.81]; P(nonadjusted)  = .003, P(adjusted) 
       = .014). Our results did not support the causal association of circulating CRP 
      with lung cancer risk. However, circulating CRP could be a prediagnostic marker 
      of lung cancer as long as 8 years in advance for current smokers.
CI  - (c) 2021 UICC.
FAU - Ji, Mengmeng
AU  - Ji M
AD  - Department of Epidemiology, School of Public Health, Southeast University, 
      Nanjing, China.
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
FAU - Du, Lingbin
AU  - Du L
AUID- ORCID: 0000-0002-1992-7784
AD  - Department of Cancer Prevention, The Cancer Hospital of the University of Chinese 
      Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
AD  - Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 
      Hangzhou, China.
FAU - Ma, Zhimin
AU  - Ma Z
AD  - Department of Epidemiology, School of Public Health, Southeast University, 
      Nanjing, China.
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
FAU - Xie, Junxing
AU  - Xie J
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
FAU - Huang, Yanqian
AU  - Huang Y
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
FAU - Wei, Xiaoxia
AU  - Wei X
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
FAU - Jiang, Xiangxiang
AU  - Jiang X
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
FAU - Xu, Jing
AU  - Xu J
AUID- ORCID: 0000-0002-8050-6831
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Yin, Rong
AU  - Yin R
AD  - Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and 
      Translational Cancer Research, Jiangsu Cancer Hospital, Jiangsu Institute of 
      Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, 
      Nanjing, China.
FAU - Wang, Yuzhuo
AU  - Wang Y
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
AD  - Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and 
      Translational Cancer Research, Jiangsu Cancer Hospital, Jiangsu Institute of 
      Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, 
      Nanjing, China.
FAU - Dai, Juncheng
AU  - Dai J
AUID- ORCID: 0000-0002-3909-5671
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
AD  - Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, China.
FAU - Jin, Guangfu
AU  - Jin G
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
AD  - Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, China.
FAU - Xu, Lin
AU  - Xu L
AD  - Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and 
      Translational Cancer Research, Jiangsu Cancer Hospital, Jiangsu Institute of 
      Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, 
      Nanjing, China.
FAU - Zhu, Chen
AU  - Zhu C
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
AD  - Department of Cancer Prevention, The Cancer Hospital of the University of Chinese 
      Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
AD  - Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 
      Hangzhou, China.
FAU - Hu, Zhibin
AU  - Hu Z
AUID- ORCID: 0000-0002-8277-5234
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
AD  - Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, China.
FAU - Ma, Hongxia
AU  - Ma H
AUID- ORCID: 0000-0002-2462-9693
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
AD  - Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, China.
FAU - Zhu, Meng
AU  - Zhu M
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
AD  - Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and 
      Translational Cancer Research, Jiangsu Cancer Hospital, Jiangsu Institute of 
      Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, 
      Nanjing, China.
AD  - Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, China.
FAU - Shen, Hongbing
AU  - Shen H
AUID- ORCID: 0000-0002-2581-5906
AD  - Department of Epidemiology, School of Public Health, Southeast University, 
      Nanjing, China.
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
AD  - Department of Cancer Prevention, The Cancer Hospital of the University of Chinese 
      Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
AD  - Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, China.
AD  - Research Units of Cohort Study on Cardiovascular Diseases and Cancers, Chinese 
      Academy of Medical Sciences, Beijing, China.
LA  - eng
GR  - MC_PC_17228/MRC_/Medical Research Council/United Kingdom
GR  - MC_QA137853/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210909
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Biomarkers, Tumor)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adenocarcinoma of Lung/blood/*epidemiology/genetics
MH  - Biological Specimen Banks
MH  - Biomarkers, Tumor/*blood
MH  - C-Reactive Protein/*analysis
MH  - Carcinoma, Non-Small-Cell Lung/blood/*epidemiology/genetics
MH  - Carcinoma, Squamous Cell/blood/*epidemiology/genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Mendelian Randomization Analysis
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
MH  - Prognosis
MH  - Prospective Studies
MH  - Small Cell Lung Carcinoma/blood/*epidemiology/genetics
MH  - United Kingdom/epidemiology
OTO - NOTNLM
OT  - C-reactive protein
OT  - Mendelian randomization
OT  - chronic inflammation
OT  - lung cancer
OT  - prediagnostic marker
EDAT- 2021/08/28 06:00
MHDA- 2021/12/21 06:00
CRDT- 2021/08/27 17:40
PHST- 2021/08/06 00:00 [revised]
PHST- 2021/01/25 00:00 [received]
PHST- 2021/08/09 00:00 [accepted]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/12/21 06:00 [medline]
PHST- 2021/08/27 17:40 [entrez]
AID - 10.1002/ijc.33780 [doi]
PST - ppublish
SO  - Int J Cancer. 2022 Jan 1;150(1):47-55. doi: 10.1002/ijc.33780. Epub 2021 Sep 9.